The UAE News web report: Moderna Inc’s experimental vaccine is 94.5 per cent effective in preventing Covid-19 based on interim data from a late-stage trial, the company said on Monday, becoming the second US drugmaker to report results that far exceed expectations.
Together with Pfizer Inc’s vaccine, which is also more than 90 per cent effective, and pending more safety data and regulatory review, the United States could have two vaccines authorized for emergency use in December with as many as 60 million doses of vaccine available this year.
Also read: Pfizer vaccine brings strong hopes to end Covid-19
The vaccines, both developed with new technology known as messenger RNA (mRNA), represent powerful tools to fight a pandemic that has infected 54 million people worldwide and killed 1.3 million.
Unlike Pfizer’s vaccine, Moderna’s shot can be stored at normal fridge temperatures, which should make it easier to distribute, a critical factor as Covid-19 cases are soaring, hitting new records in the United States and pushing some European countries back into lockdowns.
“We are going to have a vaccine that can stop Covid-19,” Moderna President Stephen Hoge said in a telephone interview.
Moderna’s interim analysis was based on 95 infections among trial participants who received the vaccine or a placebo. Only five infections occurred in volunteers who received the vaccine mRNA-1273, which is administered in two shots 28 days apart.
“The vaccine is really the light at the end of the tunnel,” Dr. Anthony Fauci, the top US infectious diseases expert said. He urged Americans not to let their guard down and to continue washing hands and being vigilant about social distancing.
Moderna expects to have enough safety data required for US authorisation in the next week or so and expects to file for emergency use authorisation (EUA) in the coming weeks.
The company’s shares, which have more than quadrupled this year, jumped as much as 12 per cent to a record high while European stocks and Wall Street futures rose. Benchmark S&P 500 futures rose 1.3 per cent, stopping just shy of a record high, while the pan-European STOXX 600 hit its highest since Mar. 5.
Shares in Pfizer and its partner BioNTech fell 2.6 per cent and 12.9 per cent respectively while Britain’s AstraZeneca, which has yet to release any results from its late-stage vaccine trials, was down 1.1 per cent at 1425 GMT (6.25pm UAE).
Moderna’s data provide further validation of the promising but previously unproven mRNA platform, which turns the human body into a vaccine factory by coaxing cells to make virus proteins that the immune system sees as a threat and attacks.
Moderna expects the vaccine to be stable at normal fridge temperatures of 2 to 8 degrees Celsius (36 to 48°F) for 30 days and it can be stored for up to 6 months at -20C.
Pfizer’s vaccine must be shipped and stored at -70C, the sort of temperature typical of an Antarctic winter. It can be stored for up to five days at standard refrigerator temperatures, or for up to 15 days in a thermal shipping box.
The data from Moderna’s trial involving 30,000 volunteers also showed the vaccine prevented cases of severe Covid-19, a question that still remains with the Pfizer vaccine. Of the 95 cases in Moderna’s trial, 11 were severe and all 11 occurred among volunteers who got the placebo.
Moderna, part of the US government’s Operation Warp Speed programme, expects to produce about 20 million doses for the United States this year, millions of which the company has already made and is ready to ship if it gets FDA authorisation.
“Assuming we get an emergency use authorization, we’ll be ready to ship through Warp Speed almost in hours,” Hoge said. “So it could start being distributed instantly.”
The 95 cases of Covid-19 included several key groups who are at increased risk for severe disease, including 15 cases in adults aged 65 and older and 20 in participants from racially diverse groups.
“We will need much more data and a full report or publication to see if the benefit is consistent across all groups, notably the elderly, but this is definitely encouraging progress, said Stephen Evans, professor of pharmacoepidemiology, London School of Hygiene & Tropical Medicine.
For latest UAE News and breaking UAE News Click here
